A Gene-alteration Profile of Human Lung Cancer Cell Lines

Overview

Journal Hum Mutat

Specialty Genetics

Date 2009 May 28

PMID 19472407

Citations 69

Authors

Raquel Blanco

Reika Iwakawa

Moying Tang

Takashi Kohno

Barbara Angulo

Ruben Pio

Luis M Montuenga

John D Minna

Jun Yokota

Montse Sanchez-Cespedes

Affiliations

Soon will be listed here.

Abstract

Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in non-small-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.

Citing Articles

Preclinical Models for Functional Precision Lung Cancer Research.

Yu J, Kiss Z, Ma W, Liang R, Li T Cancers (Basel). 2025; 17(1.

PMID: 39796653 PMC: 11718887. DOI: 10.3390/cancers17010022.

Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells.

Dimitrov J, Maddalena M, Terlizzi C, Altobelli G, Pellegrino S, Mehmood T Front Immunol. 2024; 15:1470620.

PMID: 39430758 PMC: 11487346. DOI: 10.3389/fimmu.2024.1470620.

PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression.

Lee Y, Phua C, Yuan J, Zhang B, Lee M, Kannan S Genome Med. 2024; 16(1):91.

PMID: 39034402 PMC: 11265163. DOI: 10.1186/s13073-024-01328-1.

Lack of racial and ethnic diversity in lung cancer cell lines contributes to lung cancer health disparities.

Leon C, Manley Jr E, Neely A, Castillo J, Ramos Correa M, Velarde D Front Oncol. 2023; 13():1187585.

PMID: 38023251 PMC: 10651223. DOI: 10.3389/fonc.2023.1187585.

Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage.

Sanookpan K, Chantaravisoot N, Kalpongnukul N, Chuenjit C, Wattanathamsan O, Shoaib S Antioxidants (Basel). 2023; 12(9).

PMID: 37760080 PMC: 10525775. DOI: 10.3390/antiox12091775.

References

Medina P, Romero O, Kohno T, Montuenga L, Pio R, Yokota J . Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat. 2008; 29(5):617-22. DOI: 10.1002/humu.20730. View

Schauer I, Siriwardana S, LANGAN T, Sclafani R . Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A. 1994; 91(16):7827-31. PMC: 44495. DOI: 10.1073/pnas.91.16.7827. View

Sanchez-Cespedes M . A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007; 26(57):7825-32. DOI: 10.1038/sj.onc.1210594. View

Gymnopoulos M, Elsliger M, Vogt P . Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007; 104(13):5569-74. PMC: 1838453. DOI: 10.1073/pnas.0701005104. View

Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

Carpten J, Faber A, Horn C, Donoho G, Briggs S, Robbins C . A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007; 448(7152):439-44. DOI: 10.1038/nature05933. View

Sanchez-Cespedes M . Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer. 2003; 40(2):111-21. DOI: 10.1016/s0169-5002(03)00033-3. View

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Mitsudomi T, Viallet J, Mulshine J, Linnoila R, Minna J, Gazdar A . Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991; 6(8):1353-62. View

10.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

11.

Sumitomo K, Shimizu E, Shinohara A, Yokota J, Sone S . Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene. Int J Oncol. 1999; 14(6):1075-80. DOI: 10.3892/ijo.14.6.1075. View

12.

Murakami Y, Katahira M, Makino R, Hayashi K, Hirohashi S, Sekiya T . Inactivation of the retinoblastoma gene in a human lung carcinoma cell line detected by single-strand conformation polymorphism analysis of the polymerase chain reaction product of cDNA. Oncogene. 1991; 6(1):37-42. View

13.

Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y . Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007; 26(40):5911-8. PMC: 3457639. DOI: 10.1038/sj.onc.1210418. View

14.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

15.

Shapiro G, Edwards C, Kobzik L, Godleski J, Richards W, Sugarbaker D . Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55(3):505-9. View

16.

Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A . COSMIC 2005. Br J Cancer. 2006; 94(2):318-22. PMC: 2361125. DOI: 10.1038/sj.bjc.6602928. View

17.

Harbour J, Lai S, Whang-Peng J, Gazdar A, Minna J, Kaye F . Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241(4863):353-7. PMC: 5480895. DOI: 10.1126/science.2838909. View

18.

Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

19.

Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina P, Conde E, Tang M . Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol. 2007; 214(3):347-56. DOI: 10.1002/path.2267. View

20.

Fujita T, Kiyama M, Tomizawa Y, Kohno T, Yokota J . Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol. 1999; 15(5):927-34. DOI: 10.3892/ijo.15.5.927. View